understood, it is largely accepted that variations in prion protein conformation drive the 48 molecular changes leading to the different phenotypes. In this study, we exposed abnormal prion 49 protein aggregates, encompassing the spectrum of human prion strains, to both guanidine 50 hydrochloride and thermal unfolding. Remarkably, while exposure to increasing temperature 51 revealed significant strain-specific differences in the denaturation profile of the protein, 52 treatment with guanidine hydrochloride did not. The findings suggest that thermal and chemical 53 denaturation perturb the structure of prion protein aggregates differently. Moreover, since the 54 most thermo-stable prion protein types were those associated with the most prevalent phenotypes 55 and most rapidly and efficiently transmitting strains, the results suggest a direct correlation 56 between the strain replication efficiency and the thermo-stability of prion protein aggregates. 57
INTRODUCTION 58
Prion diseases are invariably fatal neurodegenerative disorders of humans and other mammals, 59 characterized by tissue deposition of aggregates of a misfolded, beta-sheet rich and partially 60 protease-resistant isoform (PrP Sc ) of the cellular prion protein (PrP C ). In prion diseases misfolded 61 PrP Sc , originating exogenously or spontaneously, is thought to template the structural conversion 62 of the host-encoded PrP C in an autocatalytic process (1, 2) . Intriguingly, a wealth of recent 63 evidence indicates that proteinaceous seeds serving as self-propagating prion-like agents may 64 represent a common pathogenetic mechanism in most, if not all, neurodegenerative diseases (3). 65
Despite their relative rarity, prion diseases show a wide spectrum of clinical and pathological 66 phenotypes with significant heterogeneity in disease duration, symptomatology and distribution 67 or type of brain lesions. Current classification of sporadic Creutzfeldt-Jakob disease (sCJD), the 68 most common human prion disease, includes six major disease phenotypes that strongly correlate 69 at the molecular level with the genotype at the polymorphic codon 129 (methionine, M, or 70 valine, V) of the PRNP gene (which encodes for PrP C ) and two PrP Sc profiles or types (type 1 71 and type 2) comprising distinctive physicochemical properties such as size after protease 72 treatment (respectively 21 and 19 kDa) and glycoform ratio (4, 5) . Recent studies in animal 73 models have shown that phenotypic variations among sCJD phenotypes are largely maintained 74 after transmission into genetically defined hosts, suggesting that different prion strains are the 75 main cause of this diversity (6) (7) (8) (9) (10) (11) . Although it is well established that PrP C conversion into 76 PrP Sc involves consistent changes in the secondary structure with part of the α-helical structure 77 turning into a β-sheet (12, 13), a complete structural characterization of PrP Sc has been hampered 78 by the propensity of the misfolded protein to form highly aggregated and detergent-insoluble 79 polymers. Consequently, due to the limited data available from direct structural studies (14, 15) , 80 the putative central role of PrP Sc tertiary or quaternary structure in determining the molecular 81 basis of prion strains is not yet clearly demonstrated. Several experimental data, however, 82 5 indirectly support this hypothesis, both in yeast (16) and in mammals. For example, it is largely 83 believed that the heterogeneity in fragment profile of proteinase K (PK)-digested PrP Sc , which 84 distinguishes at least some of the known prion strains, is the direct consequence of PrP Sc 85 aggregates having distinct conformations (17) (18) (19) (20) (21) . Similarly, sedimentation profiles and protease 86 sensitivity have been used as indirect markers of PrP Sc structure, and have shown a correlation 87 with strain-specific transmission properties (22) (23) (24) (25) (26) (27) . More recently, studies with rodent-adapted, 88 cloned prion strains, demonstrated that also the conformational stability of PrP Sc , measured 89 indirectly either by inducing a progressive denaturation of the protein with the chaotropic salt 90 guanidine hydrochloride (GdnHCl) or by exposing the protein to increasing temperatures in the 91 presence of SDS (sodium dodecyl sulfate), may vary among different strains (28) (29) (30) . Attempts 92 have also been made to correlate PrP Sc conformational stability to strain specific properties such 93 as replication rates, although with conflicting, opposite results in murine and hamster models 94 (28) (29) (30) . 95
Overall, despite the wealth of experimental data collected in rodents and some evidence obtained 96 in humans suggesting that phenotypic diversity is somehow related to distinct PrP Sc isoforms 97 with distinct structure, the conformational spectrum of these isoforms and their relationship to 98 the issue of prions strains are still poorly understood. In particular, a systematic analysis of the 99 conformational stability of PrP Sc aggregates across the spectrum of human prions CJD is still 100 lacking. Previous studies focused on the comparison between sCJD subtypes or between variant CJD (vCJD) and the most common sCJD type MM1 (34). 102 Furthermore, only the unfolding induced by GdnHCl was addressed whereas the thermo-stability 103 of PrP Sc has never been explored in CJD. 104
To add insights to the intriguing relationship among PrP Sc molecular types, the conformational 105 stability of abnormal PrP Sc aggregates, and the phenotypic expression of disease, we have 106 6 evaluated both guanidine-induced unfolding and thermo-stability of PrP Sc across the whole 107 spectrum of currently characterized human CJD strains. 108 109
MATERIALS AND METHODS. 110
Patients and tissues. We studied brain tissues from 60 cases of sCJD and 6 cases of vCJD. sCJD 111 tissues included the whole spectrum of pure phenotypic variants recognized by current 112 classification (5): 12 MM1, 9 VV1, 10 MV 2K, 12 VV2, 7 MM2-cortical (MM 2C), and 4 MM2-113 thalamic (MM 2T). In addition, 6 brains of sCJD MM 1+2C, the most common sCJD subtype 114 with mixed histopathologic features and the co-occurrence of PrP Sc types 1 and 2 were analyzed. 115
Each sCJD brain was classified as a "pure" or "mixed" type based on the results of 116 histopathological examination, PrP immunohistochemistry and PrP Sc typing in multiple brain 117 regions, according to Parchi et al (5) . Unfixed brain tissues were obtained at autopsy and kept 118 frozen at −80 °C until use. All samples used in this study were taken from the cerebral cortex of 119 the frontal lobe. 120
Antibodies. The following monoclonal mouse antibodies, immunoreactive with human PrP, 121 were used: 3F4 at 1:30000, which recognizes residues 106-110 (35), 12B2, at 1:8000, which 122 binds residues 89-93 (36), and SAF60 at 1:2000, which reacts with residues 157-161 (37). In 123 addition, the PrP Sc type 2-specific polyclonal antibody T2 (1:5000), which binds residues 97-103 124 (7) and the rabbit antiserum 2301 (1:3000) to human PrP residues 220-231 were used. 125
Preparation of Total Brain Homogenates (THs). After removing any residual white matter 126 from the cortical tissue sample, 50-100 mgs of gray matter were homogenized (20%, w/v) in TN-127 NP40 (100 mM Tris, 130 mM NaCl, 0,5% Nonidet P-40) at pH 7.4 (38) for the guanidine assay 128 and (10%, w/v) in LB100 (100 mM Tris, 100 mM NaCl, 10 mM EDTA, 0,5% Nonidet P-40, 129 0,5% sodium deoxycholate) at pH 6.9 (39), for the thermo-solubilisation assay (TSA). In a subset 130 of experiments having the specific purpose of reproducing a previously published protocol (32), 131 7 a clearing spin of THs at 3000 rpm for 10 minutes was performed. Total protein concentration 132 was measured using a standard colorimetric method based on bicinchoninic acid (Pierce 133 Biotechnology, Rockford, IL, USA). 134
Guanidine induced unfolding/refolding assays. Total brain homogenates (TH) were adjusted 135 to a protein concentration of 5.5 mg/ml before denaturation. Equal volumes of TH and GdnHCl 136 solutions ranging from 0 to 4 M (final concentration, ∆[GndHCl]=0.25M) were mixed and 137 incubated for 1 h at 37°C at 300 rpm (Thermomixer Confort, Eppendorf). After the addition of 138 PK at a final concentration of 8 U/ml, samples were re-incubated for another 1 h at 37°C at 300 139 rpm. Protease treatment was terminated by the addition of phenylmethylsulfonyl fluoride 140 (PMSF) at a final concentration of 3.6 mM. Samples were then precipitated in pre-chilled 141 methanol for at least 3 hrs at -20° C, re-suspended in sample buffer (final concentration 3% SDS, 142 4% β-mercaptoethanol, 10% glycerol, 2 mm EDTA, 62.5 mm Tris, pH 6.8) and boiled for 6 143 minutes. Appropriate GdnHCl working concentrations were obtained from serial dilution of a 144 8M stock solution (Thermo Scientific Pierce, Protein Biology Products). 145
To monitor PrP Sc refolding, after incubation with GdnHCl, samples were immediately diluted 146 with 19 volumes of TN-NP40 and subsequently PK-digested at the same working conditions 147 specified above, precipitated in methanol and re-suspended in sample buffer. To monitor 148 reproducibility each treatment was repeated twice. 149
In a subset of samples from 6 MM1 and 6 MM 2C brains we also performed the conformational 150 stability assay (CSA), after incubation with GdnHCl, according to a previously published 151 protocol (32). Briefly, after a clearing spin at 3000 rpm for 10 minutes, aliquots of TH were 152 mixed with aliquots of GdnHCl stock solution to have a final concentration of GdnHCl ranging 153 from 0 to 4.0 M. After 1.5 hours of incubation at room temperature, samples were precipitated 154 with 5-fold pre-chilled methanol, centrifuged at 16,000 g for 30 minutes at 4 ºC, and re-155 8 suspended by sonication in 20 μl of LB100 (pH 8.0). Each aliquot was digested with 5 U/ml PK 156 for 1 hour at 37 ºC. The reaction was stopped with 2 mM PMSF. 157
Thermo-solubilisation assays. TSA was performed according to Bett and colleagues with minor 158 modifications (30). Briefly, TH were digested with 8 U/ml PK for 1h at 37°C with mild shaking 159 (300 rpm). PK digestion was inactivated with PMSF (3,6 mM final concentration). Aliquots were 160 mixed with an equal volume of loading buffer (final concentration 1,5% SDS, 2% β-161 mercaptoethanol, 5% glycerol, 1 mM EDTA, 31,25 mM Tris, pH 6.8) and heated to temperatures 162 ranging from 25°C to 95°C (∆T=10°C) for 6 min with shaking in a thermomixer at 1000 rpm 163 before loading. To monitor reproducibility each treatment was repeated twice. 164
Western blot and quantitative analysis of protein signal. After boiling (or heating treatment) 165 proteins were resolved in 13% polyacrylamide gels using a medium-sized gel electrophoresis 166 apparatus (Criterion, Bio-Rad) and transferred to Immobilon-P membranes (Millipore Corp., 167 Billerica, MA). After blocking in 10% nonfat milk in Tween-Tris-buffered saline, membranes 168 were incubated with the primary antibody. After four washings in Tween-Tris-buffered saline, 169 membranes were incubated for 1 h with an anti-mouse or an anti-rabbit secondary antibody 170 conjugated to horseradish peroxidase (GE Healthcare; working dilution, 1:4000 or 1:3000) and 171 washed again four times in Tween-Tris-buffered saline. The immunoreactive signal was detected 172 by enhanced chemiluminescence (Immobilon Western Chemiluminescent HRP Substrate, Merck 173 Millipore) on a LAS 3000 camera (Fujifilm Corp., Tokyo, Japan). Western blot signals were 174 measured by densitometry using the software AIDA (Image Data Analyzer v.4.15, Raytest, 175 Isotopenmessgeraete GmbH, Straubenhardt, Germany). 176
For guanidine unfolding assay curves were obtained by plotting the percentage of protein 177 remaining after denaturation and PK-digestion treatments (with respect to the PK-digested but 178
GndHCl-untreated sample i.e. 0 M, referred as %PrP fold ) against the corresponding guanidine 179 concentration. 180 9 ED 50 ([GndHCl] 50 , e.g. the guanidine concentration needed to unfold 50% of PrP Sc ) for each 181 sample was calculated from the equation describing the sigmoidal curve that best fitted the 182 densitometric data (R 2 ≥ 0.95). To compare groups we also considered the percentage of protein 183 remaining after denaturation plus PK digestion at [GndHCl] = 2 M (referred as %PrP fold 2M ) and 184 the percentage of protein detected after refolding plus PK digestion at [GndHCl] = 2M (referred 185 as %PrP refold 2M ). Refolded PrP Sc was calculated by means of the formula (R-F)/N, where R = 186 PrP Sc signal detected after GdnHCl incubation, dilution and PK digestion, F = PrP Sc signal 187 detected after GdnHCl incubation without dilution and PK digestion, N = PrP Sc signal detected 188 after PK digestion without GdnHCl addition. 189
For the TSA we plotted the percentage of protein solubilized after heating treatment (with 190 respect to the sample treated at 95°C, referred as %PrP Sc mon ) against the corresponding heating 191 temperature. The ED 50 (T 50 , e.g. the temperature needed to solubilize 50% of PrP Sc ) for each 192 sample was calculated from the equation describing the sigmoidal curve that best fitted the data 193 (R 2 ≥ 0.95). To compare groups we also considered the percentage of protein remaining after 194 treatment at T = 35°C (referred as %PrP Sc mon 35°C) and at T = 75°C (referred as %PrP Sc mon 75°C). 195
Statistical analyses. Statistical analyses were performed with Sigma Plot 12.5 (Systat Software  196 Inc., Chicago, IL). One-way analysis of variance (ANOVA) followed by all pairwise multiple 197 comparison procedures were used to look for significant differences in the chosen parameters 198 among CJD variants. 199
RESULTS 200

Analysis of molecular mechanisms associated with GndHCl induced unfolding of human 201
PrP Sc . It is well established that the exposure of PrP Sc to increasing concentrations of GdnHCl 202 progressively makes the protein more sensitive to protease digestion. Moreover, while a larger 203 than 3 M concentration of the chaotropic denaturant irreversibly modifies PrP Sc structure and 204 protease-resistance, milder conditions allow the structural change to be reversible (38). Studies 205 on PrP Sc extracted from Syrian hamster brains also showed that GdnHCl induced unfolding 206 mainly involves the N-terminal portion of PrP Sc , as suggested by the persistence of a PK-207 resistant, GPI-linked, proteolytic fragment of about 16 kDa over a wide range of GdnHCl 208 concentrations (40). 209
Before proceeding with the systematic analysis of the effects of GdnHCl-induced unfolding on 210 human prions, we carried out preliminary studies aimed to select the most appropriate 211 experimental conditions. We first compared the effect of PK digestion when performed before or 212 after GdnHCl dilution, and unexpectedly found that the concentration of the denaturing agent 213 that is required to fully digest PrP27-30 was significantly lower when PK was added to the 214 undiluted sample. Indeed, after GdnHCl serial dilution we noticed a rapid partial recovery of 215 PrP Sc protease-resistance. Only treatments with GdnHCl concentrations of 3.5-4 M irreversibly 216 denatured the protein after solubilisation and made it completely PK-sensitive ( Fig. 1) . Given the 217 observed rapid recovery of PrP Sc original conformation and the notion that PK is not 218 significantly inhibited by GdnHCl even at a relatively high concentration (41, 42), we chose to 219 perform PK digestions in the undiluted denaturing agent (i.e. PK hydrolysis in buffer containing 220 GdnHCl). To select the most appropriate antibody for monitoring the effect of GdnHCl on PrP Sc 221 PK-sensitivity, we compared the 3F4 antibody, which recognizes a central PrP epitope (35), with 222 antibodies against distinct C-terminal epitopes, which are known to recognize PrP Sc truncated 223 fragments, in addition to PrP . In contrast to 3F4, which only revealed PrP Sc 27-30, 224 11 C-terminal antibodies also showed variable amounts of a 18 kDa fragment, consistent with PrP C -225 C1 (43), and of a 7-8 kDa fragment, likely generated by endogenous proteolysis of PrP C during 226 the one hour incubation at 37°C preceding PK-digestion. Given the presence of these fragments 227 in untreated control samples and the lack of any correlation between the relative amount of such 228 fragments and GdnHCl concentration, we concluded that: (i) the generation of these PrP Sc 229 fragments is not denaturation-dependent, (ii) central antibodies such as 3F4 are more appropriate 230 than C-terminal antibodies to study the effect of GndHCl on PrP Sc structure. 231
PrP Sc isolates associated with distinct human prion strains show similar denaturation 232 curves after exposure to GndHCl. Guanidine denaturation curves showed a similar sigmoid 233 profile in all CJD samples analysed ( Fig. 2A, B) . The curve that best fitted the data (R 2 ≥ 0.95) 234 was a four parameter sigmoid equation. Calculated values for [GdnHCl] 50 ranged from 0,86 M 235 (sCJDVV2) to 1,03 M (sCJDMM 2T) with no statistically significant differences among CJD 236 types (Fig. 2C) . A similar value trend was obtained by calculating the percentage of detectable 237
PrP Sc signal at a GndHCl concentration of 2 M (%PrP fold 2M ) (Fig. 2D) . 238
To further look for strain-specific effects of GdnHCl, we also calculated the percentage of 239 refolded PrP Sc (%PrP refold 2M ; see methods) at a given, intermediate GdnHCl concentration (2 M). 240
In agreement with our preliminary screening, PrP Sc renaturation occurred in all groups analysed. 241 Calculated values ranged from 14% to 29%, but, again, with no statistically significant 242 differences among CJD types (Table 1) . 243
In order to exclude that the divergent results previously obtained by Cali et al. (32) on MM1 and 244 MM 2C prions would only reflect a difference in the methodology used, we also repeated the 245 experiments in a subgroup of samples following their protocol (32). The results obtained 246 confirmed the lack of remarkable differences between MM1 and MM 2C (Fig. 3) PrP Sc aggregates associated with distinct human prion strains show a divergent response to 251 thermal solubilisation. It has been shown that the exposure of PK digested PrP Sc to a thermal 252 gradient in the presence of SDS induces a progressive "solubilisation" of protein aggregates 253 which can be measured by a semi-quantitative immunoblot analysis of monomeric PrP Sc (30). By 254 applying this experimental approach to the full spectrum of human prions, we found that, at 255 variance with the GdnHCl assay, the specific profile of the calculated solubilisation curve and of 256 T 50 , %PrP Sc mon 35°C and %PrP Sc mon 75°C associated values, varied significantly according to the 257 CJD type ( Fig. 4 and 5) . Overall, while PrP Sc aggregates in sCJD VV1, and to a lesser extent in 258 MM 2T or MM 2C showed a relatively high sensitivity to thermal solubilisation, those associated 259 with MM1, VV2, and MV 2K were significantly more resistant. Hence, on the basis of the 260 analysed parameters, CJD types could be grossly classified in three groups: resistant (MM1, 261 VV2, MV2K), sensitive (vCJD, MM2C, and MM2T) and highly sensitive (VV1) to thermal 262 solubilisation. A further heterogeneity was observed within the sensitive group with vCJD prions 263 showing a more "resistant" profile at the highest temperatures in comparison to MM 2T and MM 264 2C (Fig. 5D) . 265
To exclude the possibility that the observed heterogeneity in the thermo-stability of PrP Sc 266 aggregates derives from conformational changes that are limited to the 3F4 binding region, we 267 re-analyzed a subgroup of MM1 and VV1 samples using the mAb SAF60. The thermo-268 solubilisation curves calculated from the immunoblots labeled with SAF60 fully matched those 269 obtained using 3F4 (Fig. 4) . In addition, the 13 kDa C-terminal fragment that is visualized by this 270 antibody (20) in addition to PrP27-30, showed a solubilization kinetics that paralleled that of 271 PrP27-30 in each CJD type (e.g. more thermostable in MM1 than in VV1) (Fig. 4) . The latter 272 13 observation strongly suggests that PrP Sc aggregates in CJD MM1 and VV1 include both 273
fragments. 274
Finally we plotted the solubilisation curves for each of the three PrP Sc glycoforms and found a 275 similar thermo-solubilisation kinetics for each of them with only a minor trend toward a 276 preferential solubilisation of the di-and monoglycosylated forms (data not shown). 277
PrP Sc types co-occurrence in mixed sCJD phenotypes does not alter/affect thermal 278 solubilisation properties of coexisting isoforms. It is well known that PrP Sc types 1 and 2 279 coexist within the same brain in about 35% of sCJD cases (5). Accordingly, mixed phenotypes 280 have been considered as distinct subtypes in current sCJD classification (44). However, the 281 critical question of whether the brain co-occurrence of PrP Sc types simply reflects the neutral 282 coexistence of two prion strains forming independent protein aggregates, or in contrast represents 283 interacting strains forming mixed aggregates with distinct physicochemical properties, remains 284 unanswered. To investigate this issue we selected 6 cortical samples from sCJD MM1+2C 285 containing a significant amount of both types (e.g. with the less represented type 2 being between 286 30 and 50% of the total PrP Sc signal). We calculated the solubilisation curves for these samples 287 using three different antibodies. More specifically, we monitored the solubilisation trend of the 288 two PrP Sc types simultaneously using 3F4, and analysed PrP Sc types 1 and 2 separately, despite 289 their co-occurrence, with the type-specific antibodies 12B2 and T2 (Fig. 6A) . Remarkably, the 290 curves generated with the 12B2 and T2 antibodies fully matched or paralleled very closely those 291 of the corresponding pure phenotype (Fig. 6B) . Accordingly, no significant statistical differences 292 were observed in the calculated T 50, %PrP Sc mon 35°C and %PrP Sc mon 75°C values between mixed 293 and pure samples for both PrP Sc types 1 and 2. Moreover, statistical analysis confirmed the 294 differences between PrP Sc types 1 and 2 when analysed in mixed samples using the type-specific 295 antibodies (Fig. 6C, D, E) . 296 297 14
DISCUSSION. 298
The analysis of GdnHCl-induced unfolding by either the conformation-dependent immunoassay 299 (CDI), which measures the extent of epitope exposure, or the conformational stability assay 300 (CSA), which, instead, monitors the progressive loss of PK-resistance after exposure to 301 increasing concentrations of GdnHCl, has been extensively applied to the study of PrP Sc 302 molecules. CDI analysis of PrP Sc unfolding in different murine prion strains yielded unique 303 binding profiles, suggesting that each strain is related to a specific PrP Sc conformation (45). 304
Similarly, the stability of PrP Sc aggregates measured by CSA or by a thermal stability assay 305 (TSA) was found strain-dependent and inversely correlated with the capacity to induce a rapidly 306 lethal disease in murine models (30). At variance with experimentally cloned rodent prion 307 strains, however, less numerous and less conclusive data have been obtained with PrP Sc 308 preparations extracted from naturally occurring prion diseases, especially in humans. In the few 309 studies performed to date, sCJDMM1 PrP Sc was shown to be more stable than MM 2C PrP Sc by 310 both CDI and CSA, and MM1 PrP Sc to have a moderately higher stability than vCJD PrP Sc by 311 CDI (32-34). In the present study, we have carried out the first systematic analysis of PrP Sc 312 conformational stability in a large series of brain samples across the whole spectrum of human 313 sCJD and vCJD prions. Our results failed to reveal significant strain-specific differences in the 314 GdnHCl-denaturation curve of PrP Sc aggregates. Thus, despite the limitations related to the 315 methodology being rather crude, the data suggest that the intermolecular interactions modulating 316 the divergent PrP Sc aggregation propensity among CJD types (27) are not strongly targeted by 317
GdnHCl. 318
As far as CSA is concerned, we introduced some variations in the protocol to minimize PrP Sc 319 refolding, namely by performing the PK digestion step without removing or diluting GdnHCl. 320
Given that PrP Sc refolding is paralleled by an increase in PK-resistance of the protein, it is 321 expected that GndHCl dilution before PK treatment would increase the calculated [GndHCl] 50 , 322 15 and, indeed, [GndHCl] 50 values in previous studies were greater than 1.5 M, whereas our mean 323 values ranged from 0.86 M to 1.03 M. In order to exclude the possibility that the discrepant 324 results with a previous study (32) concerning MM1 and MM 2C prions, could be due to a 325 difference in the methodology used, we repeated the study of GndHCl induced PrP Sc unfolding 326 using the original protocol (32). While, as expected, the changed procedure led to an increase in 327
[GndHCl] 50 values, the results confirmed the lack of significant differences in the GdnHCl-328 denaturation curve between MM1 and MM 2C sCJD prions. 329 Another approach that has been used to characterize prion strains in mice (30, 46) The relatively high level of PrP Sc that is solubilized at relatively low temperatures in some prion 338 types is intriguing, and may suggest that these agents comprise different forms of PrP Sc . 339 Consistently, an increasing number of studies support the idea that a variable proportion of 340 abnormal PrP is made by a soluble, poorly aggregated and fairly PK-sensitive form, although its 341 specific role and relevance for disease pathogenesis remain controversial (27, 47) . Our approach, 342 focusing on PK-treated PrP Sc, did not allow us to address in depth the issue of the influence of 343 this putative "fully PK-sensitive PrP Sc " on thermostability profile; nevertheless the lack of an 344 obvious correlation between sedimentation profile (as determined in 27), and thermostability 345 (present work) of PK-treated PrP Sc suggest that factors other than size also contribute to the 346 thermo-stability of PrP Sc aggregates in CJD. 347
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The present results, when combined with the growing knowledge on human prion strains, 348 provide novel insights into the relationships between the physicochemical properties of PrP Sc 349 aggregates and disease characteristics such as incidence, phenotypic expression, and 350 transmission properties (5, 7, 10, 11, (48) (49) (50) (51) . In particular, PrP Sc thermo-stability appears to largely, 351 although not entirely, correlate with prion replication efficiency expressed by either attack rate 352 and incubation time after experimental transmission in the most compatible host genotype or by 353 relative incidence and duration of clinical disease (Table 2) . In this regard, the comparison 354 between VV2 and VV1 human prions appears to be particularly illustrative. Indeed, when 355 compared to VV1, VV2 prions are more common, cause a more rapid disease (5), are more 356 readily transmissible (10), and produce PrP Sc aggregates with a higher thermo-stability, PK-357 resistance, and aggregation propensity ( the thermo-stability of PrP Sc seems to positively correlate with disease severity and "virulence" 361 in the most compatible host genotype. It is noteworthy that our observation is also consistent 362 with data obtained with hamster-adapted prion strains, showing that short incubation period 363 strains are characterized by a higher conformational stability of PrP Sc and a more efficient 364 replication (28, 29) . 365
Our results also reveal a relatively high thermo-stability, comparable to that of VV2, for MM1 366 and MV 2K prions. For the latter, the results are consistent with data from transmission studies 367
showing that sCJD VV2 and MV 2K are linked to the same prion strain (V2) (9), whereas the 368 result obtained with MM1 further confirms the positive correlation between PrP Sc thermo-369 stability and strain "virulence" (Table 2) . However, the degree of PK-resistance of PrP Sc 370 aggregates in MM1 is not as high as in VV2 and MV 2K (27), indicating that the two variables 371 are not necessarily directly correlated (Table 2 ). Our findings that PrP Sc aggregates in vCJD 372
show a very high resistance to PK digestion (27) despite being less thermo-stable than those from 373 sCJD MM1 prions also support this conclusion. It has been suggested that PK itself may act as 374 disaggregating agent by eliminating PrP monomers (48) and thus changing the equilibrium 375 between monomers and polymers in favor of monomers. Likewise, GndHCl or heating exposure 376 also act as disaggregating agent. Thus, the divergent response we obtained using these three 377 methods suggest that propensity of PrP Sc to disaggregate is significantly affected by the type of 378 treatment, which is also in line with evidence indicating that temperature and GdnHCl destabilize 379 the folded structure of proteins by means of distinct molecular mechanisms (52) (53) (54) (55) . 380
In addition to the analyses on pure phenotypes, we performed TSA on six cases with a mixed 381 phenotype, carrying MM at PRNP codon 129, and showing the co-occurrence of PrP Sc types 1 382 and 2 in the brain. In particular, we addressed the unsolved question of whether the brain co-383 occurrence of PrP Sc types simply reflects the neutral coexistence of two prion strains forming 384 independent protein aggregates or, in contrast, interacting strains form mixed aggregates with 385 novel specific properties. At variance with the findings of a previous study (32) arguing that the 386 co-existence of types 1 and 2 in the same anatomical region may confer special conformational 387 characteristics to the mixed PrP Sc type aggregate, the results we obtained using type-specific 388 antibodies support the former hypothesis. Indeed, properties of each individual type, when co-389 existing, exactly fit those of the corresponding pure type, suggesting a lack of interaction 390 between the two PrP Sc types. The discrepant results between the two studies are difficult to 391 explain given that they were obtained using different approaches (CSA vs TSA). Unfortunately, 392 we could not address the issue further, since we failed to reveal a significant difference in PrP Sc 393 conformational stability between the pure MM1 and MM 2C types using CSA. 394 395 
